Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 14/20 | 0.47 |
| ▸ | PDE2A | O00408 | 4/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27046602 | 1.00 | F11 (0.47) | F11PDE2ATPSAB1TPSD1TPSG1 | |
| SCHEMBL24092165 | 1.00 | F11 (0.47) | F11PDE2ATPSAB1TPSD1TPSG1 | |
| SCHEMBL27043757 | 0.92 | F11 (0.42) | F11PDE2AOGA | |
| SCHEMBL16997605 | 0.91 | F11 (0.59) | F11TPSAB1TPSD1TPSG1 | |
| SCHEMBL17002109 | 0.91 | F11 (0.59) | F11TPSAB1TPSD1TPSG1 | |
| SCHEMBL16997828 | 0.91 | F11 (0.59) | F11TPSAB1TPSD1TPSG1 | |
| SCHEMBL18476472 | 0.91 | F11 (0.59) | F11TPSAB1TPSD1TPSG1 | |
| SCHEMBL16997601 | 0.90 | F11 (0.42) | F11PDE2A | |
| SCHEMBL24092130 | 0.90 | F11 (0.42) | F11PDE2A | |
| SCHEMBL24092152 | 0.90 | F11 (0.49) | F11PDE2ATPSAB1TPSD1TPSG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4309653-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Exithera Pharmaceuticals Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-11198673-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-10259785-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-9994521-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170037003-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2017-02-09 | — | — | US | disclosed |
| US-9499532-B2 | Therapeutic compounds and compositions | eXIthera Pharmaceuticals Inc. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150225389-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | eXIthera Pharmaceuticals Inc. (US) | 2015-08-13 | — | — | US | disclosed |
| WO-2015120062-A2 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | eXIthera Pharmaceuticals Inc. (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037003-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | F11 17/4885PDE2A 624/4885TPSAB1 122/4885 |
| US-11198673-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | F11 17/4885PDE2A 624/4885TPSAB1 122/4885 |
| US-10259785-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | F11 17/4885PDE2A 624/4885TPSAB1 122/4885 |
| US-20150225389-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | F11 17/4885PDE2A 624/4885TPSAB1 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.